ADMET and DMPK

ADMET and DMPK is an open access journal on absorption, distribution, metabolism, excretion, toxicology and pharmacokinetics, published since 2013 by the International Association of Physical Chemists in Zagreb and carrying a 2025 Journal Impact Factor of 5.1.《ADMET 与药物代谢动力学》（ADMET and DMPK）是一本开放获取期刊，研究药物的吸收、分布、代谢、排泄、毒理与药代动力学，2013 年起由萨格勒布的国际物理化学家协会出版，2025 年期刊影响因子为 5.1。

Scope

• The scope opens with the physicochemical properties of drug molecules and the methods used to determine them.药物分子的理化性质及其测定方法，是本刊公布范围的首要内容。
• Drug permeability and absorption, including transport across membranes and epithelial barriers, are central themes.药物渗透性与吸收，包括跨膜与跨上皮屏障的转运，是核心主题。
• Interactions of drugs with other drugs, with proteins, with membranes and with DNA are covered.涵盖药物与其他药物、蛋白质、膜以及 DNA 之间的相互作用。
• Chemical stability and degradation of drugs, together with instrumental methods used in ADMET work, are in scope.药物的化学稳定性与降解，以及 ADMET 研究中使用的仪器分析方法，均在收稿范围。
• Metabolic processes, routes of administration and excretion, and pharmacokinetic or pharmacodynamic studies form a further cluster.代谢过程、给药与排泄途径，以及药代动力学或药效学研究构成另一组主题。
• Quantitative structure-activity and structure-property relationships, ADME and pharmacokinetic modelling, and toxicology screening are welcomed.定量构效与构性关系、ADME 与药代动力学建模以及毒理学筛查均受欢迎。
• Transporter identification and characterisation complete the scope, with work on optimising ADMET properties to improve pharmacokinetic profiles especially encouraged.转运体的鉴定与表征补足收稿范围，尤其鼓励通过优化 ADMET 性质改善药代动力学特征的研究。

History

• The journal was founded in 2013 by the International Association of Physical Chemists, a Zagreb-based scientific society, and volume 1 carried four issues that year.本刊 2013 年由总部设在萨格勒布的国际物理化学家协会创办，第 1 卷当年出版四期。
• It has been electronic only from the start, with no print edition and no subscription barrier.本刊自创办起仅有电子版，不发行纸本，也不设订阅门槛。
• Articles now appear continuously and are gathered into annual volumes, the fourteenth of which is dated 2026, although the imprint still describes a quarterly frequency.文章现以连续方式发表并归入年度卷，2026 年为第 14 卷，尽管版本信息仍标注为季刊。
• Publication is under a CC BY licence and authors retain copyright, so accepted papers can be reused with attribution.出版采用（CC BY）许可协议，作者保留版权，已发表论文可在署名前提下被再利用。
• The journal is indexed in the Emerging Sources Citation Index, Scopus, PubMed Central and DOAJ, among other databases.本刊被（Emerging Sources Citation Index）、（Scopus）、（PubMed Central）与（DOAJ）等数据库收录。
• The 2025 Journal Impact Factor is 5.1, up from 4.3 in 2024, and the 2025 CiteScore is 7.5.2025 年期刊影响因子为 5.1，高于 2024 年的 4.3，2025 年 CiteScore 为 7.5。

Editors

• Zoran Mandić of the Faculty of Chemical Engineering and Technology at the University of Zagreb and Kin Tam of the Faculty of Health Sciences at the University of Macau lead the journal as editors.萨格勒布大学化学工程与技术学院的（Zoran Mandic）与澳门大学健康科学学院的（Kin Tam）担任本刊编辑。
• Three associate editors hold named remits, Kiyohiko Sugano of Ritsumeikan University for modelling and simulation, Višnja Stepanić of the Ruđer Bošković Institute for medicinal chemistry and chemical biology, and Godefridus Peters of the VU University Medical Center for oncology.三位副编辑各有分工：立命馆大学的（Kiyohiko Sugano）负责建模与模拟，（Rudjer Boskovic）研究所的（Visnja Stepanic）负责药物化学与化学生物学，阿姆斯特丹自由大学医学中心的（Godefridus Peters）负责肿瘤学。
• The board spans academia and industry, with Geoff Holdgate and Antonio Llinas of AstraZeneca, Klara Valko of Biomimetic Chromatography, Naveed Shaik of Gilead Sciences and Hong Wan of BioDuro among its members.编委会兼跨学界与产业界，成员包括（AstraZeneca）的（Geoff Holdgate）与（Antonio Llinas）、（Biomimetic Chromatography）的（Klara Valko）、（Gilead Sciences）的（Naveed Shaik）以及（BioDuro）的（Hong Wan）。
• Review is single blind, each manuscript goes to at least two independent experts, and the editors aim to finish review within two weeks of submission.评审采用单盲方式，每篇稿件送至少两位独立专家，编辑部力求在投稿后两周内完成评审。
• The acceptance rate is below 20 percent, and papers written by board members are sent to reviewers outside the board, preferably from other regions.录用率低于 20%，编委撰写的稿件送交编委会之外的审稿人，并优先选择其他地区的专家。
• No article processing charge applies to compliant manuscripts, but an administrative fee of 1,500 euros plus VAT may be levied when a submission ignores the formatting and language standards.符合规范的稿件不收取文章处理费，但若投稿无视格式与语言规范，可能被收取 1500 欧元加增值税的管理费。